Tag: KeyVibe-002 trial
Merck gives an update from the phase 2 KeyVibe-002 trial of MK-7684A, a coformulation of vibostolimab with pembrolizumab, in patients with metastatic NSCLC who have already received treatment.
The open-label portion of the non-registrational phase 2 KeyVibe-002 trial received an update from Merck, also known as…
